Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides

Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced the presentation of two posters this week at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX, April 10-14, 2018. These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein (hsCRP) levels, and persistent high triglycerides (TG) despite statin therapy due to the association with increased cardiovascular disease (CVD) risk.

As quoted in the press release:

The poster titled “Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Persistent High Triglycerides, eGFR <90 mL/min/1.73 m², and Diabetes Mellitus” showed that, consistent with overall ANCHOR study results, compared with placebo, icosapent ethyl (IPE) 4g/day significantly decreased the primary endpoint of triglycerides (TG) (−19.7%; P<0.0001) and other lipids without increasing LDL-C. Apolipoproteins and markers of oxidation and inflammation were significantly improved. This poster was authored by: Harold M. Szerlip, MD, Baylor University Medical Center Dallas, TX; Krishnaswami Vijayaraghavan, MD, Abrazo Arizona Heart Hospital, Phoenix, AZ; Christie M. Ballantyne, MD, Baylor College of Medicine and the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX; Harold E. Bays, MD, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY; Craig Granowitz, MD, PhD, Ralph T Doyle, Rebecca A. Juliano, PhD, & Sephy Philip, RPh, PharmD, Amarin Pharma, Inc., Bedminster, NJ.

Click here to read the full press release.